Abselion has expanded its Amperia assay portfolio with the launch of the Tagged Protein Quantification Kit | His-tag and Tagged Protein Sensor | His-tag Quantification, developed in collaboration with GenScript. The assays provide a ready-to-use solution for rapid and reliable measurement of His-tagged proteins, extending Amperia beyond antibody and AAV assays into broader recombinant protein research, screening and development workflows.

His-tags are widely used affinity tags for purifying and detecting recombinant proteins in bacterial, insect and mammalian systems. Traditional quantification methods such as ELISA, gels or spectrophotometry can be time-consuming and variable, especially with crude samples. Abselion’s kit provides a fast, reproducible alternative suitable for drug discovery, structural biology, therapeutic research and bioprocess development.

Amperia is a benchtop platform that uses redox electrochemical detection for automated biomolecule quantification without optics or fluidics. The new His-tag assay runs in a premix competition format and can quantify proteins directly from crude or purified samples with minimal manual handling or specialist training.

The kit includes pre-coated sensor strips, assay plates, detection reagents and buffers. The electrochemical strips are coated with GenScript’s validated antibodies, which offer broad reactivity across common His-tag variants and expression systems for robust and consistent performance. A standalone Tagged Protein Sensor | His-tag Quantification is also available, providing flexibility for a wide range of His-tag assays on Amperia.

Ruizhi Wang, CEO and founder, Abselion, said: “The His-tag launch is one of the first affinity-based, electrochemical, automated kits for crude samples and marks an important step in extending Amperia into one of the most widely used areas of protein science. By combining GenScript’s trusted antibody technology with our ready-to-use design, we are giving researchers faster, more dependable ways to quantify His-tagged proteins directly from complex samples. Together with the flexibility of a standalone sensor option, this reflects Abselion’s mission to make high-quality protein quantification more practical and accessible to meet the needs of scientists across research, development and bioprocessing.”

Higgins Qin, senior director, protein and antibody R&D, GenScript, added: “Our THE His Tag Monoclonal Antibodies are recognised for their high affinity and broad applicability across recombinant protein workflows. Incorporating these into Abselion’s Amperia system provides researchers with a solution that simplifies His-tag quantification and supports consistent measurement from crude through to purified samples. We are pleased to see GenScript’s trusted antibody technology applied in an innovative format that makes protein analysis more reliable and accessible.”

Abselion will showcase the new kit and sensor alongside the Amperia platform at PEGS Europe 2025 in Lisbon, Portugal, from 11–13 November.